Abstract
It has long been recognized that living organisms have an astonishing ability to develop biochemical survival strategies [1]. One example for such a strategy is the mammalian immune system — an adaptive response to evolutionary challenges by microorganisms. In the past, numerous attempts have been made to exploit these endogenous “biological” survival strategies for medicine. One of the first successful attempts to employ a “biological” in this regard was the introduction of the variola vaccine by Jenner in 1796, at a time when the armamentarium of traditional chemical drugs had been notoriously poor. In the beginning of the 20th century, however, a revolution in chemistry and pharmacology overshadowed the “biological” by a “xenobiotic” concept and led to an explosion of our therapeutic options by providing the more than 10,000 traditional chemicals that we employ in medical practice today. Although our 100 years of experience with traditional chemicals have proven extremely successful, major challenges to our current drug development strategies have arisen by concerns about side effect profiles of many drugs and a perceived reduction in research productivity [1, 2]. Since the dawn of the 21st century we have witnessed the long expected and increasingly successful implementation of biotechnology derived pharmaceuticals (“biologicals”) in the medical practice. The term “biotechnology” was allegedly coined by Karl Ereky, a hungarian engineer in 1919 and related to techniques that had been employed by mankind for thousands of years to produce improved food products e.g. beer by the Sumerians as early as 6000 B.C. In contrast to the more traditional small molecular chemicals, biologicals are derived from living organisms like bacteria, yeast or even larger animals like goat or cow. Biologicals comprise a heterogenous group of pharmaceutical products, notably blood products, recombinant proteins, gene therapeutic products and cellular products. Due to their specific characteristics, biologicals introduce major challenges to our traditional concepts of drug development and routine practice of therapeutic medicine. Biologicals can be distinguished from traditional chemicals by a number of unique features, e.g. molecule size, low thermostability, species specificity and mode of administration. Therefore, biologicals do not only constitute novel pharmaceutical agents but represent an entirely different class of drugs which, unlike chemicals, do not follow well established paths, both in development and in practical use.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Müller M (2006) Biological therapies: concepts and challenges. Wien Klin Wochenschr 118(17-18): 508–512
FDA (2004) Innovation or stagnation: challenge and opportunity on the critical path to new medical products. www.fda.gov/oc/initiatives/criticalpath/whitepaper.html
IBM Business Consulting Services (1998) Pharma 2005 — an industrial revolution in R&D. www-1.ibm.com/services/au/igs/pdf/gw510-9220-pharma-2005-industrial-revolution.pdf
Drews J (2000) Drug discovery: a historical perspective. Science 287: 1960–1964
Lazarou J, Pomeranz BH, Corey PN (1998) Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279: 1200–1205
Thurmann PA (2006) Adverse drugs reactions: diagnosis and assessment. Pathologe 27: 6–12
Shah RR (2005) Drugs, QTc interval prolongation and final ICH E14 guideline: an important milestone with challenges ahead. Drug Safety 28: 1009–1028
Schuster D, Laggner C, Langer T (2005) Why drugs fail — a study on side effects in new chemical entities. Curr Pharm Des 11: 3545–3559
Kaplowitz N (2005) Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 4: 489–499
Drews J (1998) Biotechnology’s metamorphosis into a drug discovery industry. Nat Biotechnol 16(Suppl): 22–25
Cavagnaro JA (2002) Preclinical safety evaluation of biotechnology-derived pharmaceuticals. Nat Rev Drug Discov 1: 469–475
Baumann A (2006) Early development of therapeutic biologics-pharmacokinetics. Curr Drug Metab 7: 15–21
Goodyear M (2006) Learning from the TGN1412trial. BMJ 332: 677–678
Editorial (2006) Urgent changes needed for authorisation of phase I trials. Lancet 367: 1214
Wacheck V (2004) Strategies for designing clinical trials for oligonucleotide therapeutics. Drug Discov Today 9: 918–923
Saul A (2005) Models of phase 1 vaccine trials: optimization of trial design to minimize risks of multiple serious adverse events. Vaccine 23: 3068–3075
Gandy S, Heppner FL (2005) Alzheimer’s amyloid immunotherapy: quo vadis? Lancet Neurol 4: 452–453
Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, Orgogozo JM (2005) AN1792(QS-21)-201 Study team. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64: 1553–1562
Langer-Gould A, Steinman L (2006) What went wrong in the natalizumab trials? Lancet 367: 708–710
Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673–1684
Chien KR (2006) Herceptin and the heart — a molecular modifier of cardiac failure. N Engl J Med 354(8): 789–790
Anonymous (2006) First biosimilar closer to approval The European Medicines Agency has recommended the approval of Sandoz’s version of human growth hormone. Nat Rev Drug Discov 5: 178–179
Sheridan C (2006) First generic biologics finally approved. Nat Rev Drug Discov 5: 445
Leader B, Baca QJ, Golan DE (2008) Protein therapeutics: a summary and pharmacological classification. Nat Rev Drug Discov 7: 21–39
Poland GA (2007) Pharmacology, Vaccinomics, and the second golden age of vaccinology. Clin Pharmacol Ther 82: 623–626
Dorner F, Eibl J, Barrett PN (1999) New technologies for vaccines. Wien Klin Wochenschr 111(5): 199–206
Dorner F, Barrett PN (1999) Vaccine technology: looking to the future. Ann Med 31(1): 51–60
Fire A, Xu SQ, Montgomery MK, Kostas SA, Driver SE, Mello CC (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391: 806–811
Sepp-Lorenzino L, Ruddy MK (2008) Challenges and opportunities for local and systemic delivery of siRNA and antisense oligonucleotides. Clin Pharmacol Ther 84: 628–632
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag/Wien
About this chapter
Cite this chapter
Müller, M. (2010). “Non-chemical” drugs: biologicals, protein therapeutics, vaccines and antisense therapeutics. In: Müller, M. (eds) Clinical Pharmacology: Current Topics and Case Studies. Springer, Vienna. https://doi.org/10.1007/978-3-7091-0144-5_20
Download citation
DOI: https://doi.org/10.1007/978-3-7091-0144-5_20
Publisher Name: Springer, Vienna
Print ISBN: 978-3-7091-0143-8
Online ISBN: 978-3-7091-0144-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)